This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Atsumi, T Articles by Koike, T Search for Related Content PubMed PubMed Citation Articles by Atsumi, T Articles by Koike, T Pubmed/NCBI databases Medline Plus Health Information Platelet Disorders Social Bookmarking                   What's this?

Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis

Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, at3tat{at}med.hokudai.ac.jp

S Furukawa

Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

O Amengual

Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

T Koike

Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan

The pathogenesis of thrombocytopenia in patients with antiphospholipid syndrome (APS) is heterogeneous. Patients with antiphospholipid antibodies (aPL) and thrombocytopenia in the absence of clinical manifestations of APS will be diagnosed and treated as idiopathic thrombocytopenic purpura. However, the presence of aPL places those individuals at particular risk for developing both bleeding and thrombotic complications. Therefore, we propose the inclusion of such patients in the subgroup ‘aPL-associated thrombocytopenia’. More attention should be devoted to this subgroup of patients to elucidate the role of aPL in the development of thrombocytopenia and to facilitate the adequate monitoring of its potential thrombotic risk.

Key Words: anticardiolipin antibodies • lupus anticoagulant • thrombosis

Lupus, Vol. 14, No. 7, 499-504 (2005)
DOI: 10.1191/0961203305lu2145rr


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Dunoyer-Geindre, F. Boehlen, R. Favier, D. Wahl, J. Musial, W. Korte, N. Satta, E. Kruithof, and P. de Moerloose Endothelial cell activation by immunoglobulins from patients with immune thrombocytopenic purpura or with antiphospholipid syndrome Haematologica, April 1, 2008; 93(4): 635 - 636. [Full Text] [PDF]

				D Alpert, L A Mandl, D Erkan, W Yin, E I Peerschke, and J E Salmon Anti-heparin platelet factor 4 antibodies in systemic lupus erythaematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome Ann Rheum Dis, March 1, 2008; 67(3): 395 - 401. [Abstract] [Full Text] [PDF]

				T. Hereng, M. Lambert, E. Hachulla, M. Samor, S. Dubucquoi, C. Caron, D. Launay, S. Morell-Dubois, V. Queyrel, and P.-Y. Hatron Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients Lupus, January 1, 2008; 17(1): 11 - 15. [Abstract] [PDF]

				K Schallmoser, C Rosin, R Vormittag, M Brunner, D Dunkler, I Pabinger, and S Panzer Specificities of Platelet Autoantibodies and Platelet Activation in Lupus Anticoagulant Patients: A Relation to their History of Thromboembolic Disease Lupus, August 1, 2006; 15(8): 507 - 514. [Abstract] [PDF]

				J Fortea, V Obach, R Cervera, and A I Gamarra Letter to the Editor Lupus, January 1, 2006; 15(1): 58 - 58. [PDF]